YGION Biomedical
YGION Biomedical GmbH develops individualized neoantigen-based cancer vaccines. Their YGNITE™ technology platform identifies, produces, and targets the delivery of relevant peptide neoepitopes to activate the patient's immune system. This results in safe, potent, and precise targeted cancer treatment.
Funding Round: Series A
Funding Amount: €15M
Date: 21-May-2024
Investors: An Austrian private trust
Markets: Biotechnology, Oncology, Immunotherapy
HQ: Vienna, Vienna, Austria
Founded: 2022
Website: http://www.ybion.bio/
LinkedIn: https://www.linkedin.com/company/ygion-biomedical/
Leave a Comment
Comments
No comments yet.